# A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

> **NCT06931028** · PHASE3 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Sleep Apnea
- Obstructive
- Obesity

## Interventions

- **OTHER:** placebo
- **DRUG:** IBI362

## Key facts

- **NCT ID:** NCT06931028
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-05-07
- **Final completion:** 2027-06-11
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931028, "A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06931028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*